Infant Bacterial Therapeutics AB (publ) (IBT-B.ST)
Infant Bacterial Therapeutics AB (publ) operates in the Biotechnology industry of the Healthcare sector, headquartered in Stockholm, AB, SE. The stock last traded at $68.10, up 2.71% on the session, giving a market capitalisation of $886.5M. Its beta of 0.36 implies it has historically moved less than the broad market.
Infant Bacterial Therapeutics AB (publ) operates as a clinical stage pharmaceutical company develops and markets drugs to prevent serious neonatal diseases affecting premature infants in Sweden. The company's lead drug candidate is IBP-9414, which is in Phase III clinical studies to prevent necrotizing enterocolitis, as well as to improve feeding tolerance in premature infants. It is also developing IBP-1016 for the treatment of gastroschisis, a rare and severe birth abnormality in infants. In addition, its drug candidates include IBP-1118 to prevent retinopathy of prematurity that causes blindness in premature babies; and IBP-1122, indicated to eliminate vancomycin resistant enterococci that cause antibiotic resistant hospital infections. The company was incorporated in 2011 and is based in Stockholm, Sweden.
Infant Bacterial Therapeutics AB (publ) is most often compared with the following Healthcare names: